Key Takeaways
- Clinical Bottom Line
- Halting the Cascade Before It Starts
Clinical Bottom Line
| Medication Class | 2026 Resection Protocol | Clinical Risk Strategy |
|---|---|---|
| Aspirin 81mg | Continue. DO NOT hold. | Risk of stopping aspirin (stent thrombosis) heavily outweighs the minor risk of post-polypectomy mucosal bleeding. |
| Warfarin (Coumadin) | Hold 5-7 days; bridge if massive thrombotic risk (e.g., mechanical mitigation). | INR must be documented ≤ 1.5 on the morning of massive resections. |
| DOACs (Apixaban, Rivaroxaban) | Hold strictly 2 to 3 days depending on specific renal clearance. | DOAC half-lives are predictable; never bridge due to massive compounded bleeding rates. |
Halting the Cascade Before It Starts
The vast majority of lethal complications in ambulatory endoscopy are not driven by intra-procedural technical failures, but by disorganized pre-procedural evaluation. Specifically, executing an unplanned hot snare polypectomy on a patient actively taking Direct Oral Anticoagulants (DOACs) virtually guarantees an emergency room visit for severe delayed lower gastrointestinal hemorrhage.
The Mandatory “Time-Out”
Modern endoscopy suites operate under the WHO-style surgical safety checklist. Before the endoscopist deploys a snare, a hard “Time-Out” must occur where the nursing staff formally verifies the patient’s antithrombotic profile. If a 15mm polyp is discovered, but the chart verifies the patient took Apixaban that morning, the resection MUST be aborted. The pathology is thoroughly documented, and the patient must return 4 weeks later after a strictly managed, 3-day DOAC hold. Discarding this safety pause results in massive post-operative pooling of blood in the colon, severely endangering the patient and straining on-call surgical resources.
Clinical guidelines summarized by the Gastroscholar Research Team. Last updated: 2026. This article is intended for physicians.
